Catalyst Pharmaceuticals Inc (CPRX)
15.63
+0.24
(+1.56%)
USD |
NASDAQ |
Apr 16, 12:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.842B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.00% |
| Valuation | |
| PE Ratio | 25.62 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.396 |
| Price to Book Value | 4.749 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 64.87% |
Profile
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
| URL | https://www.catalystpharma.com |
| Investor Relations URL | https://ir.catalystpharma.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
| URL | https://www.catalystpharma.com |
| Investor Relations URL | https://ir.catalystpharma.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |